Current strategies for the prevention of angina in patients with stable coronary artery disease

Current Opinion in Cardiology

Volumn 21, Issue 5, 2006, Pages 492-502

  Bhatt, Ami B ^a   Stone, Peter H ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Ambulatory ischemia; Angina pectoris; Beta blockers; Calcium channel blockers; Coronary artery disease; Nicorandil

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FASUDIL; FELODIPINE; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; IVABRADINE; METOPROLOL; MOLSIDOMINE; NICORANDIL; NIFEDIPINE; NITRATE; PLACEBO; PROPRANOLOL DERIVATIVE; QUINAPRIL; RANOLAZINE; SILDENAFIL; TRIMETAZIDINE; UNINDEXED DRUG; VERAPAMIL;

CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; COUNTERPULSATION; DIZZINESS; DRUG INDUCED HEADACHE; DRUG RELEASE; EXERCISE; FLUSHING; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART PALPITATION; HUMAN; HYPOTENSION; INCIDENCE; ISCHEMIA; LIFESTYLE; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; OXYGEN SUPPLY; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; SIDE EFFECT; SPINAL CORD STIMULATION; STABLE ANGINA PECTORIS; SYNCOPE; TACHYCARDIA; UNSTABLE ANGINA PECTORIS;

EID: 33747057988     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Gibbons RJ, Abrams J, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina - summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003; 41:159-168.
2. Tunstall-Pedoe H. Angina pectoris: epidemiology and risk factors. Eur Heart J 1985; 6 (Supplement F):1-5.
3. Serruys P, Unger F, Sousa J, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001; 344:1117-1124.
4. Holubkov R, Laskey W, Haviland A, et al. Angina 1 year after percutaneous coronary intervention: a report from the NHLBI Dynamic Registry. Am Heart J 2002; 144:826-833.
5. DeMots H, Glasser S. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol 1989; 13:786-795.
6. Morrow D, Gersh B, Braunwald E. Braunwald's Heart Disease, A Textbook of Cardiovascular Medicine. 7th ed. Philadelphia: Elsevier Saunders; 2005.
7. Parker J. Nitrates and angina pectoris. Am J Cardiol 1993; 73:3C-6C.
8. Goldstein R, Rosing D, Redwood D, et al. Clinical and circulatory effects of isosorbide dinitrate. Comparison with nitroglycerin. Circulation 1971; 43:629-640.
9. Glasser SP, Michie D, Thadani U, et al. Selective reduction of heart rate with the sinus node inhibitor Zatebradine (ULFS 49) does not lead to the expected improvements in exercise duration in patients with angina pectoris. J Am Coll Cardiol 1995; 25 (2 Supplement 1):127A.
10. Nordlander R, Walter M. Once- versus twice-daily administration of controlled-release isosorbide-5-mononitrate 60mg in the treatment of stable angina pectoris: A randomized, double-blind, cross-over study. Eur Heart J 1994; 15:108-113.
11. Silber S, Vogler AC, Krause K-H, et al. Induction and circumvention of nitrate tolerance applying different dosage intervals. Am J Med 1987; 83:860-870.
12. Thadani U, Prasad R, Hamilton SF, et al. Usefulness of twice-daily isosorbide-5-mononitrate in preventing development of tolerance in angina pectoris. Am J Cardiol 1987; 60:477-482.
13. Thadani U, Maranda CR, Amsterdam E, et al. Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate. Ann Intern Med 1994; 120:353-359.
14. Kohli RS, Rodrigues EA, Kardash MM, et al. Acute and sustained effects of isosorbide 5-mononitrate in stable angina pectoris. Am J Cardiol 1986; 58:727-731.
15. Parker J. Eccentric dosing with isosorbide-5-mononitrate in angina pectoris. Am J Cardiol 1993; 72:871-876.
16. Parker JO, Amies MH, Hawkinson RW, et al. Intermittent transdermal nitroglycerin therapy in angina pectoris: clinically effective without tolerance or rebound. Circulation 1995; 91:1368-1374.
17. Ferratini M, Pirelli S, Merlini P, et al. Intermittent transdermal nitroglycerin monotherapy in stable exercise-induced angina: A comparison with a continuous schedule. Eur Heart J 1989; 10:998-1002.
18. Parker JD, Parker AB, Farrell B, et al. Intermittent transdermal nitroglycerin therapy: decreased anginal threshold during the nitrate-free interval. Circulation 1995; 91:973-978.
19. Munzel T, Sayegh H, Freeman B, et al. Evidence for enhanced vascular superoxide anion production in nitrate tolerance: a novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 1995; 95:187-194.
20. Gori T, Parker J. The puzzle of nitrate tolerance: pieces smaller than we thought? Circulation 2002; 106:2404-2408.
21. Pepine C, Cohn P, Deedwania P, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation 1994; 90:762-768.
22. Ardissino D, Savonitto S, Egstrup K, et al. Selection of medical treatment in stable angina pectoris: results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol 1995; 25:1516-1521.
23. Weiss R, Ferry D, Pickering E, et al. Effectiveness of three different doses of carvedilol for exertional angina. Am J Cardiol 1998; 82:927-931.
24. Dargie HJ, Ford I, Fox KM, et al. Total Ischaemic Burden European Trial (TIBET): Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur Heart J 1996; 17:104-112.
25. Forslund L, Hjemdahl P, Held C, et al. Prognostic implications of results from exercise testing in patients with chronic stable angina pectoris treated with metoprolol or verapamil. A report from The Angina Prognosis Study In Stockholm (APSIS). Eur Heart J 2000; 21:901-910.
26. Leon MB, Rosing DR, Bonow RO, et al. Clinical efficacy of verapamil alone and combined with propranolol in treating patients with chronic stable angina pectoris. Am J Cardiol 1981; 48:131-139.
27. Glasser SP, Gana TJ, Pascual LG, et al. Efficacy and safety of a once-daily graded-release diltiazem formulation dosed at bedtime compared to placebo and to morning dosing in chronic stable angina pectoris. Am Heart J 2005; 149:e1-e9.
28. Ezekowitz MD, Hossack K, Mehta JL, et al. Amlodipine in chronic stable angina: Results of a multicenter double-blind crossover trial. Am Heart J 1995; 129:527-535.
29. Deanfield JE, Detry JM, Lichtlen PR, et al. Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: double-blind Circadian Anti-ischemia Program in Europe (CAPE Trial). J Am Coll Cardiol 1994; 24:1460-1467.
30. Ekelund LG, Ulvenstam G, Walldius G, et al. Effects of felodipine versus nifedipine on exercise tolerance in stable angina pectoris. Am J Cardiol 1994; 73:658-660.
31. Nissen S, Tuzcu E, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. J Am Med Assoc 2004; 292:2217-2225.
32. Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing {beta}-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999; 281:1927-1936.
33. Dunselman PHJM, van Kempen LHJ, Bouwens LHM, et al. Value of the addition of amlodipine to atenolol in patients with angina pectoris despite adequate beta blockade. Am J Cardiol 1998; 81:128-132.
34. Davies RF, Habibi H, Klinke WP, et al. Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. J Am Coll Cardiol 1995; 25:619-625.
35. Boden W, Bough E, Reichman M, et al. Beneficial effects of high-dose diltiazem in patients with persistent effort angina on beta-blockers and nitrates: a randomized, double-blind, placebo-controlled cross-over study. Circulation 1985; 71:1197-1205.
36. Stone PH, Lloyd-Jones DM, Johnstone M, et al. Vascular basis for the treatment of myocardial ischemia study: Trial design and baseline characteristics. Am Heart J 2004; 147:875-882.
37. Stone PH, Lloyd-Jones DM, Kinlay S, et al. Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the vascular basis for the treatment of myocardial ischemia study. Circulation 2005; 111:1747-1755. This study thoroughly investigates the effects of statins on anginal symptoms and on ECG evidence of ischemia both in daily activities as well as in response to exercise.
38. Activity of angiotensin converting enzyme in blood serum of patients with stable effort angina. Kardiologia 2006; 46:10-12.
39. Pepine CJ, Rouleau J-L, Annis K, et al. Effects of angiotensin-converting enzyme inhibition on transient ischemia: The quinapril antiischemia and symptoms of angina reduction (QUASAR) trial. J Am Coll Cardiol 2003; 42:2049-2059.
40. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA guidelines for coronary artery bypass graft surgery: A report of the American College of Cardiology/American Heart Association task force on Practice Guidelines (Committee to revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol 1999; 34:1262-1347.
41. Davies RF, Goldberg AD, Forman S, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) Study Two-Year Follow-up: Outcomes of Patients Randomized to Initial Strategies of Medical Therapy Versus Revascularization. Circulation 1997; 95:2037-2043.
42. Bourassa M, Pepine C, Forman S, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study: effects of coronary angioplasty and coronary artery bypass graft surgery on recurrent angina and ischemia. The ACIP investigators. J Am Coll Cardiol 1995; 26:606-614.
43. Bourassa MG, Knatterud GL, Pepine CJ, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) Study: Improvement of Cardiac Ischemia at 1 Year After PTCA and CABG. Circulation 1995; 92:1-7.
44. Bucher HC, Hengstler P, Schindler C, et al. Percutaneous transluminal coronary angioplasty versus medical treatment for nonacute coronary heart disease: meta-analysis of randomised controlled trials. BMJ 2000; 321:73-77.
45. Henderson RA, Pocock SJ, Clayton TC, et al. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol 2003; 42:1161-1170.
46. Michalsen A, Knoblauch N, Lehmann N, et al. Effects of lifestyle modification on the progression of coronary atherosclerosis, autonomic function, and angina: The role of GNB3 C825T polymorphism. Am Heart J 2006; 151:870-877. This study uses an aggressive, but reasonable, long-term plan for lifestyle modification and demonstrates its ability to significantly improve angina. The treatment of patients with a predisposing genetic polymorphism is a provocative approach.
47. Yoshinaga K, Beanlands R, deKemp R, et al. Effect of exercise training on myocardial blood flow in patients with stable coronary artery disease. Am Heart J 2006; 151:1324.e11-1324.e18.
48. Chaitman BR. Ranolazine for the Treatment of Chronic Angina and Potential Use in Other Cardiovascular Conditions. Circulation 2006; 113:2462-2472.
49. Chaitman BR, Skettino SL, Parker JO, et al. Antiischemic effects and longterm survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004; 43:1375-1382.
50. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004; 291:309-316.
51. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006; 27:42-48.
52. Stone PH, Gratsiansky NA, Blokhin A, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) Trial. J Am Coll Cardiol (in press).
53. Chazov EI, Lepakchin VK, Zharova EA, et al. Trimetazidine in Angina Combination Therapy: the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am J Ther 2005; 12:35-42.
54. Marzilli M, Klein W. Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials. Coron Artery Dis 2003; 14:171-179.
55. Rosano GMC, Marazzi G, Patrizi R, et al. Comparison of trimetazidine plus sildenafil to chronic nitrates in the control of myocardial ischemia during sexual activity in patients with coronary artery disease. Am J Cardiol 2005; 95:327-331.
56. Borer JS, Fox K, Jaillon P, et al. Antianginal and Antiischemic Effects of Ivabradine, an If Inhibitor, in Stable Angina: A Randomized, Double-Blind, Multicentered, Placebo-Controlled Trial. Circulation 2003; 107:817-823.
57. Tardif J-C, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26:2529-2536.
58. Vilaine JP. The discovery of the selective If current inhibitor ivabradine: A new therapeutic approach to ischemic heart disease. Pharmacol Res 2006; 53:424-434.
59. Vicari RM, Chaitman B, Keefe D, et al. Efficacy and Safety of Fasudil in Patients With Stable Angina: A Double-Blind, Placebo-Controlled, Phase 2 Trial. J Am Coll Cardiol 2005; 46:1803-1811.
60. Di Somma S, Liguori V, Petitto M, et al. A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris. Cardiovasc Drugs Ther 1993; 7:119-123.
61. Doring G. Antianginal and antiischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. J Cardiovasc Pharmacol 1992; 20 (Supplement 3):S74-S81.
62. Group SS. Comparison of the antiischaemic and antianginal effect of nicorandil and amlodipine in patients with symptomatic stable angina pectoris: the SWAN study. J Clin Basic Cardiol 1999; 2:213-217.
63. Walker A, McMurray J, Stewart S, et al. Economic evaluation of the impact of nicorandil in angina (IONA) trial. Heart 2006; 92:619-624.
64. The IONA Study G. Determinants of coronary events in patients with stable angina: Results from the Impact of Nicorandil in Angina Study. Am Heart J 2005; 150:689.e1-689.e9.
65. Messin R, Opolski G, Fenyvesi T, et al. Efficacy and safety of molsidomine once-a-day in patients with stable angina pectoris. Int J Cardiol 2005; 98:79-89.
66. Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) Trial in Patients With Stable Angina Pectoris. Circulation 2002; 105:1291-1297.
67. Henry T, Annex B, Azrin M, et al. Final results of the VIVA trial of rhVEGF for human therapeutic angiogenesis. Circulation 1999; 100 (Suppl I):1-476.
68. Henry TD, Annex BH, McKendall GR, et al. The VIVA Trial: Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis. Circulation 2003; 107:1359-1365.
69. Kastrup J, Jorgensen E, Ruck A, et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris: A randomized double-blind placebo-controlled study: The Euroinject One trial. J Am Coll Cardiol 2005; 45:982-988.
70. Stys TP, Lawson WE, Hui JCK, et al. Effects of enhanced external counterpulsation on stress radionuclide coronary perfusion and exercise capacity in chronic stable angina pectoris. Am J Cardiol 2002; 89:822-824.
71. McCullough PA, Silver MA, Kennard ED, et al. Impact of body mass index on outcomes of enhanced external counterpulsation therapy. Am Heart J 2006; 151:139.e9-139.e13.
72. Pettersson T, Bondesson S, Cojocaru D, et al. One year follow-up of patients with refractory angina pectoris treated with enhanced external counterpulsation. BMC Cardiovasc Disord 2006; 6:28.
73. Michaels AD, Barsness GW, Soran O, et al. Frequency and efficacy of repeat enhanced external counterpulsation for stable angina pectoris (from the International EECP Patient Registry). Am J Cardiol 2005; 95:394-397.
74. Michaels AD, Raisinghani A, Soran O, et al. The effects of enhanced external counterpulsation on myocardial perfusion in patients with stable angina: A multicenter radionuclide study. Am Heart J 2005; 150:1066-1073.
75. Di Pede F, Lanza GA, Zuin G, et al. Immediate and long-term clinical outcome after spinal cord stimulation for refractory stable angina pectoris. Am J Cardiol 2003; 91:951-955.
76. Chua R, Keogh A. Spinal cord stimulation significantly improves refractory angina pectoris - a local experience: spinal cord stimulation in refractory angina. Heart Lung Circ 2005; 14:3-7.
77. Lanza GA, Sestito A, Sgueglia GA, et al. Effect of spinal cord stimulation on spontaneous and stress-induced angina and 'ischemia-like' ST-segment depression in patients with cardiac syndrome X. Eur Heart J 2005; 26: 983-989.
78. Mannheimer C, Eliasson T, Augustinsson L-E, et al. Electrical Stimulation Versus Coronary Artery Bypass Surgery in Severe Angina Pectoris: The ESBY Study. Circulation 1998; 97:1157-1163.
79. Oesterle SN, Sanborn TA, Ali N, et al. Percutaneous transmyocardial laser revascularisation for severe angina: the PACIFIC randomised trial: Potential Class Improvement FROM Intramyocardial Channels. Lancet 2000; 356:1705-1710.
80. Burkhoff D, Schmidt S, Schulman SP, et al. Transmyocardial laser revascularisation compared with continued medical therapy for treatment of refractory angina pectoris: a prospective randomised trial. Lancet 1999; 354:885-890.
81. Aaberge L, Rootwelt K, Smith H, et al. Effects of transmyocardial revascularization on myocardial perfusion and systolic function assessed by nuclear and magnetic resonance imaging methods. Scand Cardiovasc J 2001; 35:8-13.
82. McNab D, Khan SN, Sharples LD, et al. An open label, single-centre, randomized trial of spinal cord stimulation vs. percutaneous myocardial laser revascularization in patients with refractory angina pectoris: the SPiRiT trial. Eur Heart J 2006; 27:1048-1053.